See the DrugPatentWatch profile for cosentyx

Based on the information available, there is no inherent safety concern with resuming Cosentyx (secukinumab) administration after receiving a Measles, Mumps, and Rubella (MMR) vaccine. However, it is important to note that the MMR vaccine and Cosentyx work in different ways and target different systems of the body.

The MMR vaccine stimulates the immune system to produce a response against the measles, mumps, and rubella viruses, providing protection against these diseases. On the other hand, Cosentyx is a medication used to treat several inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It works by blocking the action of a specific protein involved in inflammation, helping to reduce symptoms and prevent joint damage.

According to DrugPatentWatch.com, there are currently no known interactions between the MMR vaccine and Cosentyx. Nevertheless, it is always recommended to consult with a healthcare professional before making any decisions regarding medication administration and vaccination schedules. They can provide personalized advice based on an individual's medical history and current health status.

In summary, based on the available information, there is no evidence suggesting that it is unsafe to resume Cosentyx administration post MMR vaccine administration. However, it is always best to consult with a healthcare professional for personalized advice.

Sources:

1. DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) Drug Patent Information. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>